This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Park, H. Articles by Santen, R. J. Search for Related Content PubMed PubMed Citation Articles by Park, H. Articles by Santen, R. J.

Effects of Tetramethoxystilbene on Hormone-Resistant Breast Cancer Cells: Biological and Biochemical Mechanisms of Action

¹ Endocrinology and Metabolism and ² Biostatistics, University of Virginia Health System, Charlottesville, Virginia; ³ Department of Surgery, Kyungpook National University Hospital, Daegu, South Korea; ⁴ Neuroscience Research Institute, University of California, Santa Barbara, California; ⁵ Core Endocrine Laboratory, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and ⁶ Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, South Korea

Requests for reprints: Richard J. Santen, Department of Internal Medicine, University of Virginia, P.O. Box 801416 Charlottesville, VA 22908. Phone: 434-924-2207; Fax: 434-924-1284; E-mail: rjs5y{at}virginia.edu.

Secondary resistance to hormonal therapy for breast cancer commonly develops after an initial response to tamoxifen or aromatase inhibitors. Agents to abrogate these adaptive changes would substantially enhance the long-term benefits of hormonal therapy. Our studies with a stilbene derivative called TMS (2,3',4,5'-tetramethoxystilbene) identified unexpected effects with potential utility for treatment of breast tumors secondarily resistant to hormonal therapy. TMS was originally developed as an inhibitor of cytochrome P450 1B1 to block the conversion of estradiol to 4-OH-estradiol. While studying this agent in three models of hormone resistance, we detected direct antitumor effects not related to its role as an inhibitor of catecholestrogens. During examination of the mechanisms involved, we showed that treatment with 3 µmol/L TMS for 24 h inhibited tubulin polymerization and microtubule formation, caused a cell cycle block at the G₂-M phase, and induced apoptosis. TMS also inhibited activated focal adhesion kinase (FAK), Akt, and mammalian target of rapamycin (mTOR) and stimulated c-jun-NH₂-kinase and p38 mitogen-activated protein kinase activity. With respect to antitumor effects, TMS at a concentrations of 0.2 to 0.3 µmol/L inhibited the growth of long-term tamoxifen-treated MCF-7 cells by 80% and fulvestrant-treated MCF-7 cells by 70%. In vivo studies, involving 8 weeks of treatment with TMS via a 30-mg s.c. implant, reduced tumor volume of tamoxifen-resistant MCF-7 breast cancer xenografts by 53%. Our data suggest that TMS is a promising therapeutic agent because of its unique ability to block several pathways involved in the development of hormone resistance. [Cancer Res 2007;67(12):5717–26]